Specialist global contract research organization Phlexglobal has announced its expansion into the United States with the opening of an office in Carlsbad, California - its first outside of Europe.
Also in the announcement, made at the 46th DIA Annual Meeting in Washington, Phlexglobal, specialists in paper and electronic trial master file solutions, unveiled Aidan Nuttall PhD as US office president.
Heading up Phlexglobal, Inc. Aidan, the co-founder and president of Abingdon Life Sciences and former president of Chiltern International’s US operation, will be working to extend the company’s client base and promote its innovative electronic Trial Master File (eTMF) services including the unique PhlexEview solution.
Phlexglobal’s move to open a US operation follows a sustained period of growth in the UK and Europe, and increasing interest from current and potential US-based client companies. Aidan said: “Phlexglobal has established itself in Europe with a portfolio of niche services and I’m looking forward to extending that to our US clients.
The opening of the US office comes only months after Phlexglobal signed a landmark contract with global biopharmaceutical company UCB to implement a complete TMF management solution in the UK and US worth £12 million over the next five years.
Nicola Murgatroyd, chief executive officer of Phlexglobal, commented: “This has been a really exciting 12 months for us, having secured the ongoing contract with UCB and with our US client base steadily growing, the next logical step was to open a US office.
“I am delighted to have Aidan on board to lead our US operation. His industry experience and contacts will be invaluable to us in promoting and delivering our services to the US clinical research market.”
Phlexglobal offers a combination of clinical trial knowledge, document management skills, technical expertise, personnel recruitment and training to the pharmaceutical, biotechnology, medical device, CRO and healthcare industries. Its electronic Trial Master File (eTMF) solution, PhlexEview, is a quality controlled end-to-end process enabling the electronic searching and viewing of centralized TMF documentation from sponsors, subsidiaries, CROs and field-based personnel.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Fast Tracks Johnson & Johnson’s Nipocalimab for Fetal Neonatal Alloimmune Thrombocytopenia
March 27th 2024Johnson & Johnson is moving forward with a pair of Phase III trials of nipocalimab to reduce the risk of fetal neonatal alloimmune thrombocytopenia in alloimmunized pregnant patients.